Анемический синдром у онкологических больных

Зубрихина Галина Николаевна, Valentina Nikolaevna Blindar, Матвеева Ирина Ивановна et al. · Вестник РОНЦ им. Н. Н. Блохина РАМН · 2009

The purpose of this study was to analyze erythron status in cancer patients before and during chemotherapy, to assess adequacy of endogenous erythropoietin to anemia severity in anemia of chronic disease. A total of 121 patients with anemia managed at the clinics of N. N. Blokhin RCRC RAMS for 1 month were assessed. Complete blood cell count was made using an Advia 120 (Bayer, Austria) hematology analyzer. Reticulocyte count was made in blood smears. Plasma ferritin, soluble transferrin receptor and endogenous erythropoietin levels were measured by enzyme immunoassay. Anemia of chronic disease, i. e. normochromic normocytic anemia with high or normal ferritin and low or lower limit of normal transferring concentrations was diagnosed in 89 (74%) cases. Mixed type anemia, i. e. anemia of chronic disease with evidence of latent or manifested iron deficiency, was diagnosed in 15 patients, and iron deficiency anemia resulting from chronic blood loss was reported in another 17 patients. Adequate erythropoietin reaction to anemia was detected in 18% of cases. Before chemotherapy, erythropoietin level corresponded to mild anemia (more than 70 mU/ml) in 7 (30%), and was low (7 to 45 mU/ml) in the remaining 16 cases. On chemotherapy, erythropoietin level (118 to 898 mU/ml) corresponded to moderate or marked anemia in 7 (20.6%) after 1 to 3 chemotherapy cycles and in 2 (6.2%) after 6 to 8 cycles. Endogenous erythropoietin level may be a useful prognostic factor of response to human recombinant erythropoietin and should be taken into account in prescribing this treatment.

Cited by 0 works.

Authors